Revolution Medicines (RVMD) director receives stock awards and options grant

Rhea-AI Filing Summary

Revolution Medicines director Alexis Borisy reported equity awards from the company. He received 1,191 shares of Common Stock as a grant, bringing his direct holdings to 2,340,075 shares after the transaction. He was also granted options to purchase 3,127 shares of Common Stock at an exercise price of $162.99 per share, expiring on June 18, 2036.

The 1,191 granted shares are structured as restricted stock units. The option will vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting after the grant date, as long as Borisy continues as a Service Provider under the company’s 2020 Plan.

Insights

Insider trading and equity compensation analyst

Routine director equity awards; no open-market buying or selling.

Alexis Borisy received equity compensation from Revolution Medicines in the form of 1,191 restricted stock units and options on 3,127 shares at an exercise price of $162.99 per share. The awards cost him nothing upfront and are typical for a non-employee director.

The options vest in a single tranche on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting, contingent on his continued service. After the grant, he directly holds 2,340,075 common shares. With no open-market purchases or sales disclosed, this filing mainly updates his compensation-based ownership.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Borisy Alexis

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	3,127	$0.00	--
Grant/Award	Common Stock	1,191	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 3,127 shares (Direct, null); Common Stock — 2,340,075 shares (Direct, null)

Footnotes (1)

1. Includes 1,191 restricted stock units. Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

Key Figures

RSU grant: 1,191 shares Option grant size: 3,127 shares Option exercise price: $162.99 per share +2 more

5 metrics

RSU grant 1,191 shares Restricted stock units included in holdings

Option grant size 3,127 shares Stock Option (Right to Buy) underlying shares

Option exercise price $162.99 per share Conversion or exercise price for stock option

Option expiration June 18, 2036 Expiration date of stock option grant

Shares after transaction 2,340,075 shares Total Common Stock held directly after awards

Key Terms

restricted stock units, Stock Option (Right to Buy, Service Provider, 2020 Plan

4 terms

restricted stock units financial

"Includes 1,191 restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy financial

"Stock Option (Right to Buy) reported as a derivative security."

Service Provider financial

"subject to the Reporting Person remaining a Service Provider under the 2020 Plan"

2020 Plan financial

"as defined in the 2020 Plan through the vesting date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 05:52 PM Accepted by SEC EDGAR 06/23/2026 - 05:52 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Borisy Alexis

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DR

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2026		A		1,191	A	$0	2,340,075(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$162.99	06/18/2026		A		3,127		(2)	06/18/2036	Common Stock	3,127	$0	3,127	D

Explanation of Responses:

1. Includes 1,191 restricted stock units.

2. Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

	/s/ Jack Anders, as Attorney-in-fact for Alexis Borisy	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Alexis Borisy receive in this Form 4 for Revolution Medicines (RVMD)?

Alexis Borisy received 1,191 shares of Common Stock as restricted stock units and stock options for 3,127 shares. These equity awards are compensation grants, not open-market transactions, and increase his potential ownership stake in Revolution Medicines over time.

How many Revolution Medicines (RVMD) shares does Alexis Borisy hold after this grant?

After the reported equity grant, Alexis Borisy directly holds 2,340,075 shares of Revolution Medicines Common Stock. This figure includes the newly granted 1,191 restricted stock units, reflecting his updated direct ownership position as reported in the Form 4 filing.

What are the vesting terms of Alexis Borisy’s new stock option in RVMD?

The option covering 3,127 shares vests in full on the earlier of the first anniversary of June 18, 2026, or immediately before the next Annual Meeting after the grant. Vesting requires Borisy to remain a Service Provider under the company’s 2020 Plan through that date.

Is Alexis Borisy buying or selling Revolution Medicines (RVMD) shares in this Form 4?

He is not buying or selling shares on the open market. The Form 4 reports compensation-related acquisitions: 1,191 restricted stock units and options on 3,127 shares, both granted at no cash cost rather than purchased or sold through market transactions.

What is the exercise price and expiration date of Alexis Borisy’s new RVMD stock option?

The stock option has an exercise price of $162.99 per share and expires on June 18, 2036. Borisy can choose to exercise the option after it vests and before expiration, subject to continued service and any applicable plan or company restrictions.

How do the restricted stock units reported for RVMD affect Alexis Borisy’s ownership?

The filing notes that his holdings include 1,191 restricted stock units. These units represent a right to receive an equivalent number of shares upon vesting, which will convert into common stock and thereby further increase his actual share ownership once they settle.